zoledronic acid has been researched along with Atherosclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Fu, X; Jiang, J; Yang, J; Yang, Z; Yu, C; Yu, X | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Avanzati, A; Campagna, MS; De Paola, V; Franci, B; Gennari, L; Gozzetti, A; Lauria, F; Marchini, E; Martini, G; Merlotti, D; Nuti, R; Salvadori, S; Tozzi, M | 1 |
3 other study(ies) available for zoledronic acid and Atherosclerosis
| Article | Year |
|---|---|
Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.
Topics: Atherosclerosis; Humans; Inflammation; Nanoparticles; Reactive Oxygen Species; Zoledronic Acid | 2022 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
The effects of zoledronic acid on serum lipids in multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Cholesterol, HDL; Collagen; Diphosphonates; Female; Humans; Imidazoles; Lipids; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid | 2008 |